3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
31
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
6
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Micrometastasis
1
Lymphatic Metastasis
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
21
Cyclophosphamide
18
fludarabine
8
Radiotherapy
8
Radiosurgery
7
Nivolumab
7
poly ICLC
6
fludarabine phosphate
6
aldesleukin
6
Therapeutics
6
Paclitaxel
6
Magnetic Resonance Spectroscopy
6
durvalumab
5
Psychiatric Rehabilitation
5
Interleukin-2
5
Drug Therapy
5
Docetaxel
5
Cisplatin
5
temsirolimus
4
cemiplimab
4
Trastuzumab
4
Temozolomide
4
Sirolimus
4
Gemcitabine
4
Flow Cytometry
4
Filgrastim
4
Carboplatin
4
tremelimumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
3
pazopanib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Indocyanine Green
×
Dermatologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled